Recruiting

Nicotine

Sponsor:

Stony Brook University

Code:

NCT07095205

Conditions

Major Depressive Disorder (MDD)

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Accepted

Interventions

Nicotine transdermal patch

PET Scan with [18F] VAT

Study Details

Brief summary:

In the brain, certain nerve cells communicate using a chemical called acetylcholine. Acetylcholine is thought to be important for several functions including mood, memory and wakefulness. The purpose of this study is to explore the role of these nerve cells in depression. Also, we would like to understand how nicotine, the study drug, works in depression and how it affects these nerve cells. To do this, brain imaging will be used before and after this treatment.

Conditions

Major Depressive Disorder (MDD)

Study ID

NCT07095205

Start date

Oct 3, 2024

Status verified date

Jul, 2025

Completion date

Sep 30, 2029

Anticipated

Primary completion date

Sep 30, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Accepted

Inclusion Criteria:

For Non-Depressed Participants:

  • Age range 18 to 65 years old.
  • Capacity to consent (able to read, understand, and sign informed consent).

For Participants with MDD

  • Age range 18 to 65 years old.
  • Capacity to consent (able to read, understand, and sign informed consent).
  • Major Depressive Disorder (MDD) as primary diagnosis and currently in a major depressive episode
  • Score of at least 29 on the Montgomery-Asberg Depression Rating Scale (MADRS).

Exclusion Criteria:

For Non-Depressed Participants:

  • Nicotine use, including tobacco, e-cigarettes, nicotine patch, nicotine gum, within the past year \[except for occasional users, who cannot use nicotine products in the week before the scan\].
  • Need for use of medication during the study that will affect cholinergic levels.
  • Problematic drug/alcohol use that is judged sufficient to interfere with study procedures during the treatment period or impact participant safety.
  • Significant active physical illness or neurological deficit that may affect brain function or imaging.
  • Significant eye conditions such as keratoconus and/or need for rigid contact lenses.
  • Current or lifetime history of a major psychiatric diagnosis.
  • Any MRI contraindications, including recent tattoos, metal implants, pacemaker, metal prostheses, orthodontic appliances, or presence of shrapnel that are contraindicated for MRI.
  • Any PET contraindications, including if study imaging will result in the participant receiving greater exposure than the research limit, or if participant is pregnant, currently breastfeeding, or planning to conceive during the course of study participation.
  • Blood donation within 8 weeks of the \[18F\]VAT scan.

For Participants with MDD

  • Nicotine use, including tobacco, e-cigarettes, nicotine patch, nicotine gum, within the past year \[except for occasional users, who cannot use nicotine products in the week before the scan\].
  • Currently on effective antidepressant medications or need for use of medications that target the cholinergic system.
  • Problematic drug/alcohol use that is judged sufficient to interfere with study procedures during the treatment period or impact participant safety.
  • Significant active physical illness or neurological deficit that may affect the brain function or imaging.
  • Significant eye conditions such as keratoconus and/or need for rigid contact lenses.
  • Current or lifetime major psychiatric diagnosis other than MDD.
  • Life-time history of psychosis or current psychosis.
  • Significant risk for suicide.
  • Any MRI contraindications, including recent tattoos, metal implants, pacemaker, metal prostheses, orthodontic appliances, or presence of shrapnel that are contraindicated for MRI.
  • Any PET contraindications, including if study imaging will result in the participant receiving greater exposure than the research limit, or if participant is pregnant, currently breastfeeding, or planning to conceive during the course of study participation.
  • Blood donation within 8 weeks of the \[18F\]VAT scan.

Study Design

Enrollment

14 participants

Anticipated

Allocation

Non randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Control

This arm consists of non-depressed participants. These participants will receive one PET scan utilizing tracer \[18F\] VAT to measure cholinergic terminal density.

experimental: Major Depressive Disorder (MDD)

This arm consists of participants diagnosed with Major Depressive Disorder. Participants in the MDD arm will receive interventional treatment for 8 days with transdermal nicotine patches. Participants in the MDD arm will also receive two PET scans with \[18F\]VAT tracer: one at baseline and one post-treatment.

Interventions

Nicotine transdermal patch

The participants with MDD will receive Nicorette NicoDerm CQ nicotine transdermal patches for 8 days (7 mg/day for days 1-2, 14 mg/day for days 3-4, and 21 mg/day for days 5-8).

PET Scan with [18F] VAT

All participants will undergo a PET scan at Baseline using tracer \[18F\] VAT. Participants with MDD will undergo a second post-treatment PET scan using tracer \[18F\] VAT.

Primary outcome measure

  • Change in Hamilton Depression Rating Scale-17 (HAMD) score. [ Time Frame: Before and after 8 days of treatment with nicotine. ]

Central Contacts and Locations

Locations

Stony Brook University: Dept of Psychiatry

Recruiting

Stony Brook, New York, United States, 11794

Contacts

More Information

Sponsor

Stony Brook University

Last update posted

Jul 31, 2025

Last verified

Jul, 2025

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Stony Brook University on 2025-07-31.